The Effect of Dopamine Agonists on Adaptive and Aberrant Salience in Parkinson's Disease
Open accessAbstract
Clinical evidence suggests that after initiation of dopaminergic medications some patients with Parkinson's disease (PD) develop psychotic symptoms, such as hallucinations and delusions. Here, we tested the hypothesis that the neurocognitive basis of this phenomenon can be defined as the formation of arbitrary and illusory associations between conditioned stimuli and reward signals, called aberrant salience. Young, never-medicated PD patients and matched controls were assessed on a speeded reaction time task in which the probe stimulus was preceded by conditioned stimuli that could signal monetary reward by color or shape. The patients and controls were re-evaluated after 12 weeks during which the patients received a dopamine agonist (pramipexole or ropinirole). Results indicated that dopamine agonists increased both adaptive and aberrant salience in PD patients, that is, formation of real and illusory associations between conditioned stimuli and reward, respectively. This effect was present when associations were assessed by means of faster responding after conditioned stimuli signaling reward (implicit salience) and overt rating of stimulus-reward links (explicit salience). However, unusual feelings and experiences, which are subclinical manifestations of psychotic-like symptoms, were specifically related to irrelevant and illusory stimulus-reward associations (aberrant salience) in PD patients receiving dopamine agonists. The learning of relevant and real stimulus-reward associations (adaptive salience) was not related to unusual experiences. These results suggest that dopamine agonists may increase psychotic-like experiences in young patients with PD, possibly by facilitating dopaminergic transmission in the ventral striatum, which results in aberrant associations between conditioned stimuli and reward.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In some circumstances, pramipexole impairs behavioral learning, possibly by disrupting phasic dopaminergic signaling, in reinforcement learning tasks and other learning or decision making tasks.
“In some circumstances, pramipexole impairs behavioral learning, possibly by disrupting phasic dopaminergic signaling, in reinforcement learning tasks (Nagy et al. 2012; Pizzagalli et al. 2008), and other learning or decision making tasks (Haley Gallant et al. 2016).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Nagy et al. 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1× · see citing works
“Neurological and psychiatric symptoms were assessed using the Hoehn–Yahr Scale (Hoehn and Yahr, 1967), the Unified Parkinson’s Disease Rating Scale (UPDRS) (Lang and Fahn, 1989), the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A) (Mountjoy and Roth, 1982), and the Young Mania Ratin…”
MethodHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · see citing works
The role of the basal ganglia in habit formation
Yin, H. H., & Knowlton, B. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1919 · Cited by 2,402 · see citing works
The debate over dopamine’s role in reward: the case for incentive salience
Berridge, K. C. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0578-x · Cited by 2,347 · see citing works
By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism
Frank, M. J., Seeberger, L. C., & O'Reilly, R. C. (2004) · Science · doi:10.1126/science.1102941 · Cited by 1,964 · see citing works
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K. S., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,945 · see citing works
Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
Pessiglione, M., Seymour, B., Flandin, G., Dolan, R. J., & Frith, C. D. (2006) · Nature · doi:10.1038/nature05051 · Cited by 1,584 · see citing works
Multiple dopamine functions at different time courses
Schultz, W. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135722 · Cited by 1,415 · see citing works
Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism
Frank, M. J., Samanta, J., Moustafa, A. A., & Sherman, S. J. (2007) · Science · doi:10.1126/science.1146157 · Cited by 1,116 · see citing works
Cools, R. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.12.1136 · Cited by 906 · see citing works
‘Frontal' cognitive function in patients with Parkinson's disease ‘on' and ‘off' levodopa
GOTHAM, A. M., BROWN, R. G., & MARSDEN, C. D. (1988) · Brain · doi:10.1093/brain/111.2.299 · Cited by 835 · see citing works
Wyvell, C. L., & Berridge, K. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-21-08122.2000 · Cited by 764 · cited 1× · see citing works
“It has also been shown that conditioned stimuli increase the speed of responses, and this effect is mediated by dopaminergic signals in the ventral striatum (Wyvell and Berridge, 2000).”
BackgroundFrom reinforcement learning models to psychiatric and neurological disorders
Maia, T. V., & Frank, M. J. (2011) · Nature Neuroscience · doi:10.1038/nn.2723 · Cited by 715 · see citing works
New scales for the assessment of schizotypy
Mason, O., Claridge, G., & Jackson, M. C. (1995) · Personality and Individual Differences · doi:10.1016/0191-8869(94)00132-c · Cited by 654 · see citing works
Cools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(03)00117-9 · Cited by 516 · see citing works
Parkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D. A., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 422 · see citing works
Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Voon, V., & Fox, S. H. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1089 · Cited by 397 · see citing works
Measuring Socioeconomic Status
Cirino, P. T., Chin, C. E., Sevcik, R. A., Wolf, M., Lovett, M. W., & Morris, R. D. (2002) · Assessment · doi:10.1177/10791102009002005 · Cited by 371 · see citing works
Altered awareness of action in schizophrenia: a specific deficit in predicting action consequences
Voss, M., Moore, J., Hauser, M., Gallinat, J., Heinz, A., & Haggard, P. (2010) · Brain · doi:10.1093/brain/awq152 · Cited by 366 · see citing works
Bódi, N., Kéri, S., Nagy, H., Moustafa, A. A., Myers, C. E., Daw, N. D., Dibó, G., Takáts, A., Bereczki, D., & Gluck, M. A. (2009) · Brain · doi:10.1093/brain/awp094 · Cited by 356 · see citing works
Self-citationReversal learning in Parkinson's disease depends on medication status and outcome valence
Cools, R., Altamirano, L. J., & D’Esposito, M. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.03.030 · Cited by 286 · see citing works
Do patients with schizophrenia exhibit aberrant salience?
Roiser, J. P., Stephan, K. E., den Ouden, H. E. M., Barnes, T. R. E., Friston, K. J., & Joyce, E. M. (2009) · Psychological Medicine · doi:10.1017/s0033291708003863 · Cited by 262 · see citing works
McGowan, S., Lawrence, A., Sales, T., Quested, D., & Grasby, P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.134 · Cited by 251 · see citing works
Assessment of Parkinsonʼs Disease
Larsen, T., Calne, S. M., & Calne, D. B. (1984) · Clinical Neuropharmacology · doi:10.1097/00002826-198406000-00008 · Cited by 230 · see citing works
Gerlach, M., Double, K. L., Arzberger, T., Leblhuber, F., Tatschner, T., & Riederer, P. F. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0027-5 · Cited by 187 · see citing works
Quantification of neurologic deficit
Wiles, C. M. (1990) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.7.628 · Cited by 186 · see citing works
Kosaka, H., Omori, M., Murata, T., Iidaka, T., Yamada, H., Okada, T., Takahashi, T., Sadato, N., Itoh, H., Yonekura, Y., et al. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00324-3 · Cited by 184 · see citing works
Mehler‐Wex, C., Riederer, P. F., & Gerlach, M. (2006) · Neurotoxicity Research · doi:10.1007/bf03033354 · Cited by 181 · see citing works
Housden, C. R., O’Sullivan, S. S., Joyce, E. M., Lees, A. J., & Roiser, J. P. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.84 · Cited by 176 · see citing works
Amphetamine modulates human incentive processing
Knutson, B., Bjork, J. M., Fong, G. W., Hommer, D., Mattay, V. S., & Weinberger, D. R. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.030 · Cited by 174 · see citing works
van Eimeren, T., Ballanger, B., Pellecchia, G., Miyasaki, J. M., Lang, A. E., & Strafella, A. P. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.124 · Cited by 162 · see citing works
Enhanced frontal function in Parkinson's disease
Cools, R., Miyakawa, A., Sheridan, M. A., & D’Esposito, M. (2009) · Brain · doi:10.1093/brain/awp301 · Cited by 155 · see citing works
l-dopa impairs learning, but spares generalization, in Parkinson's disease
Daphna Shohamy, A., Myers, C. E., Geghman, K. D., Sage, J., & Gluck, M. A. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2005.07.013 · Cited by 152 · see citing works
van Eimeren, T., Ballanger, B., Pellecchia, G., et al. (2009) · Neuropsychopharmacology · doi:10.1038/sj.npp.npp2009124 · Cited by 144 · see citing works
MacDonald, P. A., MacDonald, A. A., Seergobin, K. N., Tamjeedi, R., Ganjavi, H., Provost, J.-S., & Monchi, O. (2011) · Brain · doi:10.1093/brain/awr075 · Cited by 122 · see citing works
Medication impairs probabilistic classification learning in Parkinson's disease
Jahanshahi, M., Wilkinson, L., Gahir, H., Dharminda, A., & Lagnado, D. A. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.12.010 · Cited by 118 · see citing works
Dopaminergic medication boosts action–effect binding in Parkinson's disease
Moore, J. W., Schneider, S. A., Schwingenschuh, P., Moretto, G., Bhatia, K. P., & Haggard, P. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.12.014 · Cited by 114 · see citing works
Winstanley, C. A., Cocker, P. J., & Rogers, R. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.230 · Cited by 98 · see citing works
Pramipexole modulates the neural network of reward anticipation
Ye, Z., Hammer, A., Càmara, E., & Münte, T. F. (2010) · Human Brain Mapping · doi:10.1002/hbm.21067 · Cited by 95 · see citing works
Chaotic behavior in dopamine neurodynamics.
King, R., Barchas, J. D., & Huberman, B. A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1244 · Cited by 91 · see citing works
Studies in the relationship between depressive disorders and anxiety states
Mountjoy, C. Q., & Roth, M. (1982) · Journal of Affective Disorders · doi:10.1016/0165-0327(82)90043-x · Cited by 88 · see citing works
Top–Down Attentional Control in Parkinson's Disease: Salient Considerations
Cools, R., Rogers, R. D., Barker, R. A., & Robbins, T. W. (2009) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21227 · Cited by 84 · see citing works
Ecker, D., Unrath, A., Kassubek, J., & Sabolek, M. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-23 · Cited by 83 · see citing works
Kobayakawa, M., Tsuruya, N., & Kawamura, M. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.04.011 · Cited by 58 · see citing works
Differential Influence of Levodopa on Reward-Based Learning in Parkinson's Disease
Graef, S., Biele, G., Krugel, L. K., Marzinzik, F., Wahl, M., Wotka, J., Klostermann, F., & Heekeren, H. R. (2010) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2010.00169 · Cited by 54 · see citing works
Adaptive and aberrant reward prediction signals in the human brain
Roiser, J. P., Stephan, K. E., den Ouden, H. E. M., Friston, K. J., & Joyce, E. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.075 · Cited by 52 · see citing works
Delusions, superstitious conditioning and chaotic dopamine neurodynamics
Shaner, A. L. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0656 · Cited by 49 · see citing works
Miller, R. J. (1993) · International review of neurobiology · doi:10.1016/s0074-7742(08)60571-1 · Cited by 35 · see citing works
Ishibashi, K., Ishii, K., Oda, K., Mizusawa, H., & Ishiwata, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017723 · Cited by 32 · see citing works
Assessing the construct validity of aberrant salience
Schmidt, K. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.058.2009 · Cited by 32 · see citing works
Psychotic and compulsive symptoms in Parkinson's disease
Verbaan, D., van Rooden, S. M., Jeukens‐Visser, M., Marinus, J., Emre, M., & van Hilten, J. J. (2009) · Movement Disorders · doi:10.1002/mds.22453 · Cited by 31 · see citing works
Eye movements in visual search indicate impaired saliency processing in Parkinson's disease
Mannan, S. K., Hodgson, T. L., Masud Husain, B., & Christopher Kennard, C. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00679-1 · Cited by 26 · see citing works
Dopamine boosts memory for angry faces in Parkinson's disease
Subramanian, L., Hindle, J. V., Jackson, M. C., & Linden, D. E. J. (2010) · Movement Disorders · doi:10.1002/mds.23420 · Cited by 21 · see citing works
Stoner, S. C., Dahmen, M. M., Makos, M., Lea, J. W., Carver, L. J., & Rasu, R. S. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m183 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
From prediction error to incentive salience: mesolimbic computation of reward motivation.
Berridge, K. C. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.07990.x · Cited by 700 · see citing works
More than skin deep: Stress neurobiology and mental health consequences of racial discrimination
Berger, M., & Sarnyai, Z. (2015) · Stress · doi:10.3109/10253890.2014.989204 · Cited by 606 · see citing works
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293 · see citing works
Pain and analgesia: the value of salience circuits
Borsook, D., Edwards, R., Elman, I., Becerra, L., & Levine, J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.003 · Cited by 215 · see citing works
Dopamine, reward learning, and active inference
FitzGerald, T. H. B., Dolan, R. J., & Friston, K. (2015) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2015.00136 · Cited by 112 · see citing works
Incentive motivation: ‘wanting’ roles of central amygdala circuitry
Warlow, S. M., & Berridge, K. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113376 · Cited by 64 · see citing works
Striatal dopamine, reward, and decision making in schizophrenia
Deserno, L., Schlagenhauf, F., & Heinz, A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/ldeserno · Cited by 58 · see citing works
Modulation of motivational salience processing during the early stages of psychosis
Smieskova, R., Roiser, J. P., Chaddock, C. A., Schmidt, A., Harrisberger, F., Bendfeldt, K., Simon, A., Walter, A., Fusar-Poli, P., McGuire, P. K., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.036 · Cited by 56 · see citing works
Taddei, R. N., Çankaya, Ş., Dhaliwal, S., & Chaudhuri, К. R. (2017) · Parkinson s Disease · doi:10.1155/2017/3256542 · Cited by 55 · see citing works
Dopaminergic signaling of uncertainty and the aetiology of gambling addiction
Zack, M. H., George, R. S., & Clark, L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109853 · Cited by 54 · see citing works
Murray, G. K., Knolle, F., Ersche, K. D., Craig, K. J., Abbott, S., Shabbir, S. S., Fineberg, N. A., Suckling, J., Sahakian, B. J., Bullmore, E. T., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05292-2 · Cited by 53 · see citing works
Boehme, R., Deserno, L., Gleich, T., Katthagen, T., Pankow, A., Behr, J., Buchert, R., Roiser, J. P., Heinz, A., & Schlagenhauf, F. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0805-15.2015 · Cited by 52 · see citing works
Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease
Jaakkola, E., Joutsa, J., Mäkinen, E., Johansson, J. J., & Kaasinen, V. (2017) · European Journal of Neurology · doi:10.1111/ene.13390 · Cited by 39 · see citing works
McCutcheon, R. A., Bloomfield, M. A. P., Dahoun, T., Mehta, M., & Howes, O. D. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.011 · Cited by 35 · see citing works
Prefrontal cortex, dopamine, and jealousy endophenotype
Marazziti, D., Poletti, M., Dell’Osso, L., Baroni, S., & Bonuccelli, U. (2012) · CNS Spectrums · doi:10.1017/s1092852912000740 · Cited by 32 · see citing works
Katthagen, T., Dammering, F., Kathmann, N., Kaminski, J. A., Walter, H., Heinz, A., & Schlagenhauf, F. (2016) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2016.10.001 · Cited by 25 · see citing works
The effects of methylphenidate on cerebral activations to salient stimuli in healthy adults.
Farr, O. M., Hu, S., Matuskey, D., Zhang, S., Abdelghany, O., & Li, C. R. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0034465 · Cited by 23 · see citing works
Components determining the slowness of information processing in parkinson’s disease
Arroyo-Ferrer, A., Periañez, J. A., Lago, M. R., Lubrini, G., Andreo-Jover, J., Benito‐León, J., Louis, E. D., & Romero, J. P. (2021) · Brain and Behavior · doi:10.1002/brb3.2031 · Cited by 22 · see citing works
The development of delusion revisited: A transdiagnostic framework
Poletti, M., & Sambataro, F. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.07.032 · Cited by 20 · see citing works
Savchenko, A. A., Müller, C., Lubec, J., Leo, D., Korz, V., Afjehi-Sadat, L., Maliković, J., Sialana, F. J., Lübec, G., & Sukhanov, I. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.799433 · Cited by 13 · see citing works
Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments
Rojas, M., Chávez-Castillo, M., Durán, P., Ortega, Á., Bautista-Sandoval, M. J., Salazar, J. J., Riaño-Garzón, M., Chacín, M., Medina, Ó., Palmar, J., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220428102802 · Cited by 11 · see citing works
In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease
Djamshidian, A., O’Sullivan, S. S., Tomassini, A., Foltynie, T., Limousin, P. D., Avilés-Olmos, I., Warner, T. T., Lees, A. J., & Averbeck, B. B. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140388 · Cited by 11 · see citing works
Knolle, F., Garofalo, S., Viviani, R., Justicia, A., Ermakova, A. O., Blank, H., Williams, G. B., Arrondo, G., Ramachandra, P., Tudor-Sfetea, C., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102277 · Cited by 10 · see citing works
Delusional misidentification in Parkinson’s disease: report of two cases and a review
Hermanowicz, N. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1411161 · Cited by 9 · see citing works
Balog, Z., Somlai, Z., & Kéri, S. (2012) · Personality and Individual Differences · doi:10.1016/j.paid.2012.08.020 · Cited by 8 · see citing works
Self-citationKéri, S., Nagy, H., Levy‐Gigi, E., & Kelemen, O. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12350 · Cited by 8 · see citing works
Self-citationSamad, F. D. A., Sidi, H., Kumar, J., Das, S., Midin, M., & Hatta, N. H. (2017) · Current Drug Targets · doi:10.2174/1389450118666170704142708 · Cited by 8 · see citing works
From Aberrant Salience to Jumping to Conclusions
Poletti, M., & Bonuccelli, U. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182854989 · Cited by 8 · see citing works
Györfi, O., Nagy, H., Bokor, M., Kelemen, O., & Kéri, S. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1630-6 · Cited by 7 · see citing works
Self-citationPoletti, M., Frosini, D., Pagni, C., Baldacci, F., Lucetti, C., Dotto, P. D., Ceravolo, R., & Bonuccelli, U. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1874-6 · Cited by 6 · see citing works
Drug-induced delusion: A comprehensive overview of the WHO pharmacovigilance database
Balcerac, A., Baldacci, A., Romier, A., Annette, S., Lemarchand, B., Bihan, K., & Bottemanne, H. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115365 · Cited by 5 · see citing works
Kéri, S., & Kelemen, O. (2016) · Religions · doi:10.3390/rel7060073 · Cited by 5 · see citing works
Self-citationPolner, B., Moustafa, A. A., Nagy, H., Takáts, A., Györfi, O., & Kéri, S. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.037 · Cited by 5 · see citing works
Self-citationThe dark side of dopaminergic therapies in Parkinson’s disease: shedding light on aberrant salience
Poletti, M. (2017) · CNS Spectrums · doi:10.1017/s1092852917000219 · Cited by 4 · see citing works
Vaidya, B. P., Shenoy, S., & Praharaj, S. K. (2024) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_521_24 · Cited by 3 · see citing works
Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis
Oehrn, C. R., Schönenkorb, J., Timmermann, L., Nenadić, I., Weber, I., & Grant, P. S. (2021) · Scientific Reports · doi:10.1038/s41598-020-80765-5 · Cited by 3 · see citing works
Refining mechanistic models of hallucinations for enhanced translatability
Buck, J., Iigaya, K., & Horga, G. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03773-x · Cited by 2 · see citing works
Kéri, S. (2012) · Magyar Pszichológiai Szemle · doi:10.1556/mpszle.67.2012.2.3 · Cited by 2 · see citing works
Self-citationReduction in presynaptic dopamine transporter may be associated with future problematic delusion
Kataoka, H., Kinugawa, K., Sugata, M., Morita, S., Miyasaka, T., & Sugie, K. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108321 · Cited by 1 · see citing works
Rožič, P. (2015) · Project Muse (Johns Hopkins University)
Egyéni különbségek az alkotó gondolkodásban: Pszichózis az adaptív működésben?
Polner, B., & Kéri, S. (2015) · Magyar Pszichológiai Szemle · doi:10.1556/0016.2015.70.3.3
Self-citationSalience attribution in addiction and psychosis
Freeman, T. P. (2013) · UCL Discovery (University College London)
- Authors
- Nagy, H., Levy-Gigi, E., Somlai, Z., Takáts, A., Bereczki, D., & Kéri, S.
- Affiliations
- Semmelweis University (HU)
- University of Szeged (HU)
- Corresponding author
- Kéri, Szabolcs
- Venue
- Neuropsychopharmacology
- Published
- 2011-11-16
- Volume
- 37
- Issue
- 4
- Pages
- 950-958
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC3280658
- OpenAlex
- W2085102516
- Cited by
- 42
- References
- 55
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 3 · 2013: 6 · 2012: 4
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- Funders
- Hungarian Scientific Research Fund
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- Parkinson's disease, dopamine agonists, pramipexole, ropinirole, aberrant salience, psychotic-like experiences, hallucinations, delusions, ventral striatum, dopamine signaling
- MeSH terms
- Adult, Antiparkinson Agents, Cognition Disorders, Female, Humans, Illusions, Male, Middle Aged, Parkinson Disease, Psychoses, Substance-Induced, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
